Effects of Empagliflozin Treatment on Glycerol-Derived Hepatic Gluconeogenesis in Adults with Obesity: A Randomized Clinical Trial.

Ian J NeelandNatalia de Albuquerque RochaConnor HughesColby R AyersCraig R MalloyEunsook S Jin

Published in: Obesity (Silver Spring, Md.) (2020)

VAT is associated with endogenous glycerol-derived hepatic gluconeogenesis, and empagliflozin reduces endogenous glycerol gluconeogenesis in adults with obesity without T2DM. These findings suggest a mechanism by which sodium-glucose cotransporter 2 inhibitors may prevent T2DM in obesity.

Keyphrases

insulin resistance
metabolic syndrome
weight loss
high fat diet induced
type diabetes
weight gain
glycemic control
adipose tissue
body mass index
combination therapy